The FTSE 100 enjoyed another leap towards record territory as the index pushed around 0.7 per cent higher on Tuesday, ...

Japan's genome editing market, valued at USD 1.45 billion by 2033, grows at a 17.97% CAGR, driven by precision medicine and biotech investment. Key t ...

It also heralded a change in strategy, with CEO Robert Davis saying that the company is undergoing "a multiyear optimization ...

Investors were clearly impressed by the company's second-quarter beats, especially the one on the bottom line.

Consumers are already stretched thin, so rate cuts may not significantly boost spending or spark runaway inflation as many ...

"The Mounjaro (tirzepatide) Patient Information Leaflet warns that hair loss is a common side effect in patients treated with ...

The 15 percent tariff rate agreed under the new deal could significantly impact pharma firms reliant on European imports.

A formal trade agreement between the US and EU introduces a 15% tariff on most EU exports, including pharmaceuticals, ...

Partially a result, Novo Nordisk has steadily declined since last summer. Over the past year, NVO shares are down more than ...

Health plans should directly contract with drug manufacturers to provide medications at transparent and affordable prices, ...

Shares in Danish drugmaker Novo Nordisk were down nearly 20% in pre-market trading Tuesday morning after the company cuts its sales and profit estimates.

This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially ...